

Alberto A Papi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5709596/publications.pdf>

Version: 2024-02-01

289
papers

22,927
citations

10650

74
h-index

10955

142
g-index

294
all docs

294
docs citations

294
times ranked

18884
citing authors

#	ARTICLE	IF	CITATIONS
1	Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1105-1113.	2.7	17
2	Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 11-25.	5.2	109
3	From DREAM to REALTI and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 778-797.	2.7	25
4	The ICQ asthma algorithm: Inhaled corticosteroid Containing resCUE (ICQ) treatment for present and future asthma management. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1325-1327.	2.7	2
5	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. <i>European Respiratory Journal</i> , 2022, 59, 2102006.	3.1	34
6	Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 169-177.	0.5	7
7	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. <i>European Respiratory Journal</i> , 2022, 59, 2100142.	3.1	10
8	Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in England. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 35-51.	1.5	8
9	Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. <i>International Journal of COPD</i> , 2022, Volume 17, 355-370.	0.9	5
10	European Respiratory Society guidelines for the diagnosis of asthma in adults. <i>European Respiratory Journal</i> , 2022, 60, 2101585.	3.1	84
11	Indacaterol acetate/glycopyrronium bromide/mometasone furoate: a combination therapy for asthma. <i>Current Respiratory Medicine Reviews</i> , 2022, 18, .	0.1	0
12	The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 661-668.	5.2	41
13	Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. <i>Clinical and Translational Allergy</i> , 2022, 12, e12145.	1.4	4
14	Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. <i>New England Journal of Medicine</i> , 2022, 386, 2071-2083.	13.9	55
15	Lung Spatial Profiling Reveals a T Cell Signature in COPD Patients with Fatal SARS-CoV-2 Infection. <i>Cells</i> , 2022, 11, 1864.	1.8	2
16	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 17-24.	2.5	57
17	The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme. <i>European Respiratory Journal</i> , 2022, 60, 2102760.	3.1	11
18	As-needed anti-inflammatory reliever therapy for asthma management: evidence and practical considerations. <i>Clinical and Experimental Allergy</i> , 2021, 51, 873-882.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. <i>Platelets</i> , 2021, 32, 560-567.	1.1	31
20	EAACI Biologicals Guidelinesâ€”Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	2.7	156
21	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 24-36.	2.5	417
22	Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. <i>Advances in Therapy</i> , 2021, 38, 468-478.	1.3	13
23	COVIDâ€”19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 887-892.	2.7	69
24	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 69-84.	5.2	135
25	Budesonideâ€”formoterol reliever therapy in intermittent <i>versus</i> mild persistent asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003064.	3.1	10
26	From GOLD 0 to Pre-COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 414-423.	2.5	119
27	Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. <i>Drug Safety</i> , 2021, 44, 273-290.	1.4	25
28	Rate of Decline of FEV₁ as a Biomarker of Survival?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 663-665.	2.5	6
29	Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. <i>Respiratory Research</i> , 2021, 22, 25.	1.4	15
30	Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110425.	1.0	7
31	Glucocorticoids impair type I IFN signalling and enhance rhinovirus replication. <i>European Journal of Pharmacology</i> , 2021, 893, 173839.	1.7	10
32	Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. <i>Critical Care</i> , 2021, 25, 74.	2.5	94
33	Inhaled long-acting muscarinic antagonists in asthma â€” A narrative review. <i>European Journal of Internal Medicine</i> , 2021, 85, 14-22.	1.0	18
34	Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVIDâ€”19?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 961-962.	2.7	3
35	Blood Interferon-Î± Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 648004.	2.2	60
36	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 260-274.	5.2	102

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. <i>Respiratory Research</i> , 2021, 22, 90.	1.4	7
38	Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 344-356.	1.4	13
39	Beclometasone dipropionate/formoterol maintenance and reliever therapy asthma exacerbation benefit increases with blood eosinophil level. <i>European Respiratory Journal</i> , 2021, 58, 2004098.	3.1	5
40	Burden of Pertussis in COPD: A Retrospective Database Study in England. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 157-169.	0.7	21
41	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. <i>Respirology</i> , 2021, 26, 532-551.	1.3	67
42	Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. <i>Clinical and Molecular Allergy</i> , 2021, 19, 5.	0.8	14
43	Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 575-583.	1.5	36
44	The Burden of Short-Acting β_2 -Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program. <i>Advances in Therapy</i> , 2021, 38, 3816-3830.	1.3	14
45	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/LUMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 29.	1.1	6
46	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. <i>European Journal of Internal Medicine</i> , 2021, 89, 3-9.	1.0	19
47	Medical thoracoscopy without pleural fluid: How I do it. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	1
48	Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 262-265.e2.	1.5	5
49	A serum proteome signature to predict mortality in severe COVID-19 patients. <i>Life Science Alliance</i> , 2021, 4, e202101099.	1.3	62
50	Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 407-419.	1.5	16
51	Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion. <i>Viruses</i> , 2021, 13, 1855.	1.5	17
52	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1251-1258.	2.5	121
53	Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. <i>Respiratory Medicine</i> , 2021, 187, 106572.	1.3	29
54	A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care. <i>European Respiratory Journal</i> , 2021, 58, 2003599.	3.1	11

#	ARTICLE	IF	CITATIONS
55	Air Pollution Exposure Impairs Airway Epithelium IFN- γ Expression in Pre-School Children. <i>Frontiers in Immunology</i> , 2021, 12, 731968.	2.2	7
56	Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 740803.	1.6	17
57	Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥ 4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001077.	1.2	8
58	Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study. <i>Biomedicines</i> , 2021, 9, 1837.	1.4	6
59	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. <i>Lancet Respiratory Medicine</i> , 2020, 8, 158-170.	5.2	69
60	Airway inflammatory profile is correlated with symptoms in stable COPD: A longitudinal proof-of-concept cohort study. <i>Respirology</i> , 2020, 25, 80-88.	1.3	20
61	ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. <i>European Respiratory Journal</i> , 2020, 55, 1901407.	3.1	26
62	Asthma COPD Overlap PRO-CON Debate. ACO: The Mistaken Term. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 474-476.	0.7	9
63	Prevention of Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 453-462.	0.8	5
64	FN3K expression in COPD: a potential comorbidity factor for cardiovascular disease. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000714.	1.2	4
65	Use of mucolytics in COPD: A Delphi consensus study. <i>Respiratory Medicine</i> , 2020, 175, 106190.	1.3	4
66	<p>A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 3093-3103.	0.9	0
67	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	1.0	6
68	Small airway dysfunction: not so silent after all?. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1062-1063.	5.2	6
69	<p>The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 415-428.	1.5	10
70	Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. <i>Thorax</i> , 2020, 75, 1035-1039.	2.7	15
71	Management of chronic refractory cough in adults. <i>European Journal of Internal Medicine</i> , 2020, 81, 15-21.	1.0	22
72	Treatment strategies for asthma: reshaping the concept of asthma management. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 75.	0.9	55

#	ARTICLE	IF	CITATIONS
73	Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. <i>Respiratory Research</i> , 2020, 21, 285.	1.4	16
74	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. <i>ERJ Open Research</i> , 2020, 6, 00187-2019.	1.1	6
75	Achieving the balance between evidence and simplicity. <i>European Respiratory Journal</i> , 2020, 55, 2000651.	3.1	0
76	Extrafine triple therapy in patients with asthma and persistent airflow limitation. <i>European Respiratory Journal</i> , 2020, 56, 2000476.	3.1	15
77	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 671-680.	5.2	81
78	Eosinophilâ€derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2085-2088.	2.7	11
79	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1058-1068.	2.7	67
80	The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision. <i>European Respiratory Journal</i> , 2020, 56, 2000627.	3.1	10
81	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq1 1 0.784314 rgBT /O recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	2.7	232
82	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1043-1057.	2.7	85
83	SABINA: An Overview of Short-Acting Î²2-Agonist Use in Asthma in European Countries. <i>Advances in Therapy</i> , 2020, 37, 1124-1135.	1.3	84
84	Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 840-850.e7.	1.5	8
85	Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer. <i>Molecular Oncology</i> , 2020, 14, 2163-2175.	2.1	20
86	Chronic cough in adults. <i>European Journal of Internal Medicine</i> , 2020, 78, 8-16.	1.0	17
87	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. <i>ERJ Open Research</i> , 2020, 6, 00193-2020.	1.1	14
88	<p>Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 701-711.	1.5	14
89	Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 284-291.	0.7	4
90	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 745-756.	5.2	159

#	ARTICLE	IF	CITATIONS
91	IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis. <i>European Respiratory Journal</i> , 2019, 54, 1800174.	3.1	54
92	Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. <i>Lancet</i> , 2019, 394, 1737-1749.	6.3	125
93	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. <i>European Respiratory Journal</i> , 2019, 54, 1900900.	3.1	56
94	Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2019, 20, 195.	1.4	8
95	Controlled Trial of Budesonide+Formoterol as Needed for Mild Asthma. <i>New England Journal of Medicine</i> , 2019, 380, 2020-2030.	13.9	308
96	Benralizumab for the Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , 2019, 381, 1023-1034.	13.9	180
97	Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations. <i>European Respiratory Journal</i> , 2019, 53, 1900147.	3.1	6
98	Asthma progression and mortality: the role of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2019, 54, 1900491.	3.1	96
99	<p>Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 531-546.	0.9	20
100	Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 402-416.	5.2	225
101	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019, 53, 1900164.	3.1	1,223
102	Letter from Italy. <i>Respirology</i> , 2019, 24, 605-606.	1.3	1
103	Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. <i>European Respiratory Journal</i> , 2019, 53, 1900235.	3.1	15
104	Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 264.	0.8	7
105	A multinational observational study identifying primary care patients at risk of overestimation of asthma control. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 43.	1.1	20
106	Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. <i>ERJ Open Research</i> , 2019, 5, 00106-2019.	1.1	21
107	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019, 16, 29-39.	1.5	11
108	Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study. <i>Respiratory Medicine</i> , 2019, 147, 37-43.	1.3	21

#	ARTICLE	IF	CITATIONS
109	Effects of Anti-IL-5 on Virus-induced Exacerbation in Asthma. Light and Shadow. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 410-411.	2.5	3
110	Bronchial mucosal IFN- γ and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations. Journal of Allergy and Clinical Immunology, 2019, 143, 114-125.e4.	1.5	65
111	Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1989-1998.e3.	2.0	44
112	Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet, The, 2018, 391, 1076-1084.	6.3	433
113	Asthma. Lancet, The, 2018, 391, 783-800.	6.3	1,105
114	Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?. European Respiratory Journal, 2018, 51, 1702577.	3.1	4
115	TGF- β Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD. Chest, 2018, 153, 851-862.	0.4	43
116	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. European Respiratory Review, 2018, 27, 180010.	3.0	41
117	We Have to Learn to Do without Knowing Enough: Antieosinophilic Treatments for Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1-2.	2.5	10
118	Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 907-915.e7.	2.0	36
119	Deficient Immune Response to Viral Infections in Children Predicts Later Asthma Persistence. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 673-675.	2.5	15
120	Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. European Journal of Internal Medicine, 2018, 47, 82-86.	1.0	12
121	Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 111-113.	0.7	22
122	Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1223-1226.	2.5	25
123	Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International Journal of COPD, 2018, Volume 13, 3971-3981.	0.9	56
124	Inhaled triple therapy in chronic obstructive pulmonary disease – Authors' reply. Lancet, The, 2018, 392, 1113-1114.	6.3	2
125	Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients. International Journal of COPD, 2018, Volume 13, 3173-3190.	0.9	18
126	Blood eosinophils for the management of COPD patients?. Lancet Respiratory Medicine, the, 2018, 6, 807-808.	5.2	2

#	ARTICLE	IF	CITATIONS
127	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018, 52, 1801219.	3.1	166
128	Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. <i>European Respiratory Journal</i> , 2018, 52, 1801334.	3.1	16
129	Inhaled corticosteroid containing combinations and mortality in COPD. <i>European Respiratory Journal</i> , 2018, 52, 1801230.	3.1	51
130	Clinical and Pathologic Factors Predicting Future Asthma in Wheezing Children. A Longitudinal Study. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 458-466.	1.4	27
131	Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD. <i>Pharmacological Research</i> , 2018, 133, 160-169.	3.1	17
132	The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide. <i>Respiratory Research</i> , 2018, 19, 85.	1.4	20
133	Extrafine beclometasone dipropionate, formoterol fumarate, glycopyrronium (BDP/FF/G) and exacerbation recurrence: post-hoc analysis of the TRIBUTE study.. , 2018, , .		1
134	Severe asthma: phenotyping to endotyping or vice versa?. <i>European Respiratory Journal</i> , 2017, 49, 1700053.	3.1	14
135	Management of patients with early mild asthma and infrequent symptoms. <i>Lancet, The</i> , 2017, 389, 129-130.	6.3	7
136	Update in Asthma 2016. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 548-557.	2.5	5
137	Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 1919-1929.	6.3	326
138	IFN- γ /IFN- λ responses to respiratory viruses in paediatric asthma. <i>European Respiratory Journal</i> , 2017, 49, 1602489.	3.1	1
139	Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1071-1081.e9.	2.0	229
140	Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 49, 1600791.	3.1	438
141	Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1015-1024.e8.	2.0	82
142	Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial. <i>European Respiratory Journal</i> , 2017, 50, 1701183.	3.1	7
143	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 50, 1602265.	3.1	131
144	Blood eosinophil count and exacerbation risk in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700761.	3.1	64

#	ARTICLE	IF	CITATIONS
145	Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. <i>International Journal of COPD</i> , 2017, Volume 12, 1961-1971.	0.9	22
146	Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. <i>International Journal of COPD</i> , 2017, Volume 12, 2917-2928.	0.9	31
147	The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not "frequent exacerbators"; a post hoc analysis of the FORWARD study. <i>International Journal of COPD</i> , 2017, Volume 12, 3263-3271.	0.9	3
148	Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700451.	3.1	130
149	Phenomenology of COPD: interpreting phenotypes with the ECLIPSE study. <i>Monaldi Archives for Chest Disease</i> , 2016, 83, 721.	0.3	6
150	Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study. <i>Journal of Inflammation</i> , 2016, 13, 26.	1.5	2
151	The management of asthma in the phenotype and biomarker era: The proposal of a new diagnostic-therapeutic model. <i>Journal of Asthma</i> , 2016, 53, 665-667.	0.9	8
152	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 388, 2115-2127.	6.3	1,050
153	Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. <i>Respiratory Medicine</i> , 2016, 120, 54-63.	1.3	35
154	Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β_2 -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2016, 388, 963-973.	6.3	351
155	Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history. <i>International Journal of Cardiology</i> , 2016, 222, 806-812.	0.8	17
156	Extrafine beclometasone dipropionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16030.	1.1	26
157	Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. <i>Journal of Asthma</i> , 2016, 53, 321-329.	0.9	86
158	Assessing small airway impairment in mild-to-moderate smoking asthmatic patients. <i>European Respiratory Journal</i> , 2016, 47, 1264-1267.	3.1	11
159	Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. <i>European Respiratory Journal</i> , 2016, 47, 981-984.	3.1	18
160	Biomarkers of oxidative-stress and inflammation in exhaled breath condensate from hospital cleaners. <i>Biomarkers</i> , 2016, 21, 115-122.	0.9	14
161	Glycogen synthase kinase-3 β modulation of glucocorticoid responsiveness in COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L1112-L1123.	1.3	21
162	The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. <i>International Journal of COPD</i> , 2015, 10, 2431.	0.9	3

#	ARTICLE	IF	CITATIONS
163	Models of Respiratory Infections: Virus-Induced Asthma Exacerbations and Beyond. <i>Allergy, Asthma and Immunology Research</i> , 2015, 7, 525.	1.1	19
164	Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial. <i>PLoS ONE</i> , 2015, 10, e0118241.	1.1	38
165	Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2015, 191, 187-193.	0.8	69
166	An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 35, 19-27.	1.1	9
167	Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. <i>Respiratory Medicine</i> , 2015, 109, 208-217.	1.3	8
168	Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 147-157.	1.3	88
169	Phospho-p38 MAPK Expression in COPD Patients and Asthmatics and in Challenged Bronchial Epithelium. <i>Respiration</i> , 2015, 89, 329-342.	1.2	20
170	Small airway disease in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 68-73.	1.2	28
171	Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 63-67.	1.1	40
172	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	2.5	166
173	Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 560-567.	0.7	25
174	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	3.1	138
175	Combination treatment in asthma: Reviewing old and new options. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 34, 72-74.	1.1	5
176	Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study. <i>European Respiratory Journal</i> , 2015, 45, 1534-1538.	3.1	23
177	Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial. <i>Lancet Respiratory Medicine</i> , 2015, 3, 109-119.	5.2	25
178	Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. <i>Patient Related Outcome Measures</i> , 2014, 5, 153.	0.7	25
179	Quality Standards for Real-World Research. Focus on Observational Database Studies of Comparative Effectiveness. <i>Annals of the American Thoracic Society</i> , 2014, 11, S99-S104.	1.5	115
180	Severe Asthma: Pragmatic Clinical Lumping and Time for Investigational Splitting. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 619-620.	2.5	2

#	ARTICLE	IF	CITATIONS
181	Poor adherence to guidelines for long-term oxygen therapy (LTOT) in two Italian university hospitals. Internal and Emergency Medicine, 2014, 9, 319-324.	1.0	15
182	Rhinovirus-induced interferon production in asthma. Thorax, 2014, 69, 772-772.	2.7	3
183	Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.. Pulmonary Pharmacology and Therapeutics, 2014, 27, 129-138.	1.1	179
184	INSTEAD: a randomised switch trial of indacaterol <i>versus</i> salmeterol/fluticasone in moderate COPD. European Respiratory Journal, 2014, 44, 1548-1556.	3.1	121
185	Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax, 2014, 69, 516-524.	2.7	99
186	Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 2014, 451, 8-14.	1.0	69
187	Lymphocyte subsets in experimental rhinovirus infection in chronic obstructive pulmonary disease. Respiratory Medicine, 2014, 108, 78-85.	1.3	19
188	Soluble Major Histocompatibility Complex Class I-Related Chain B Molecules Are Increased and Correlate With Clinical Outcomes During Rhinovirus Infection in Healthy Subjects. Chest, 2014, 146, 32-40.	0.4	3
189	Airway Inflammation and Illness Severity in Response to Experimental Rhinovirus Infection in Asthma. Chest, 2014, 145, 1219-1229.	0.4	80
190	Neutrophil adhesion molecules in experimental rhinovirus infection in COPD. Respiratory Research, 2013, 14, 72.	1.4	23
191	Project PriMo: Sharing principles and practices of bronchodilator therapy monitoring in COPD. Pulmonary Pharmacology and Therapeutics, 2013, 26, 218-228.	1.1	20
192	Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κ B and c-Jun N-terminal kinase activation. Journal of Allergy and Clinical Immunology, 2013, 132, 1075-1085.e6.	1.5	80
193	Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective. Respiratory Medicine, 2013, 107, 1531-1537.	1.3	13
194	Beclometasoneâformoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 23-31.	5.2	125
195	Integrating real-life studies in the global therapeutic research framework. Lancet Respiratory Medicine,the, 2013, 1, e29-e30.	5.2	102
196	Midazolam in Flexible Bronchoscopy Premedication. Journal of Bronchology and Interventional Pulmonology, 2013, 20, 232-240.	0.8	12
197	Detection of exacerbations in asthma based on electronic diary data: results from the 1-year prospective BIOAIR study. Thorax, 2013, 68, 611-618.	2.7	34
198	Plasma s<sc>RAGE</sc> and <sc>N</sc>â(carboxymethyl) lysine in patients with <sc>CHF</sc> and/or <sc>COPD</sc>. European Journal of Clinical Investigation, 2013, 43, 562-569.	1.7	23

#	ARTICLE	IF	CITATIONS
199	Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2013, 22, 439-448.	2.5	39
200	Nuclear Factor κ -B Is Activated in the Pulmonary Vessels of Patients with End-Stage Idiopathic Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2013, 8, e75415.	1.1	77
201	Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study. <i>PLoS ONE</i> , 2013, 8, e80166.	1.1	19
202	Reducing Agents Decrease the Oxidative Burst and Improve Clinical Outcomes in COPD Patients: A Randomised Controlled Trial on the Effects of Sulphurous Thermal Water Inhalation. <i>Scientific World Journal, The</i> , 2013, 2013, 1-7.	0.8	17
203	Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions. <i>Current Drug Targets</i> , 2013, 14, 141-148.	1.0	21
204	Definition and aetiology of infective exacerbations of COPD. , 2013, , 58-67.		0
205	Rhinovirus Infection Induces Degradation of Antimicrobial Peptides and Secondary Bacterial Infection in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1117-1124.	2.5	238
206	Inhaled Corticosteroid/Long-Acting β_2 -Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 303-310.	0.9	19
207	Oxidative Stress-induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1026-1027.	2.5	3
208	Asthma. <i>Clinics in Chest Medicine</i> , 2012, 33, 473-484.	0.8	7
209	Defining critical roles for NF κ B p65 and type I interferon in innate immunity to rhinovirus. <i>EMBO Molecular Medicine</i> , 2012, 4, 1244-1260.	3.3	80
210	Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. <i>Respiratory Research</i> , 2012, 13, 54.	1.4	27
211	Research needs in allergy: an EAACI position paper, in collaboration with EFA. <i>Clinical and Translational Allergy</i> , 2012, 2, 21.	1.4	127
212	Cost-Effectiveness and Cost-Utility of Beclomethasone/Formoterol versus Fluticasone Propionate/Salmeterol in Patients with Moderate to Severe Asthma. <i>Clinical Drug Investigation</i> , 2012, 32, 253-265.	1.1	22
213	Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1307-1314.	1.5	167
214	A new combination therapy for asthma: bridging the gap between effectiveness in trials and clinical practice?. <i>Respiratory Medicine</i> , 2012, 106, S1-S3.	1.3	5
215	Role of Stem Cells in the Pathogenesis of COPD and Pulmonary Emphysema. , 2012, , 307-317.		1
216	Mechanisms involved in lung cancer development in COPD. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1030-1044.	1.2	83

#	ARTICLE	IF	CITATIONS
217	Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children. <i>Italian Journal of Pediatrics</i> , 2011, 37, 39.	1.0	10
218	Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. <i>Thorax</i> , 2011, 66, 521-527.	2.7	148
219	Oxidative Stress-induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 796-802.	2.5	159
220	Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 734-742.	2.5	349
221	Immune Response to Mycobacterium tuberculosis Infection in the Parietal Pleura of Patients with Tuberculous Pleurisy. <i>PLoS ONE</i> , 2011, 6, e22637.	1.1	21
222	Rescue Treatment in Asthma: Response. <i>Chest</i> , 2010, 137, 240-241.	0.4	0
223	Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD). <i>Current Pharmaceutical Design</i> , 2010, 16, 3554-3573.	0.9	25
224	A Novel Insight into Adaptive Immunity in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1011-1019.	2.5	62
225	Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 830-837.	1.5	121
226	A role for phosphoinositol 3-kinase \hat{I} in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1146-1153.	1.5	99
227	Oxidative/nitrosative stress selectively altered A _{2B} adenosine receptors in chronic obstructive pulmonary disease. <i>FASEB Journal</i> , 2010, 24, 1192-1204.	0.2	15
228	Inhaled BDP/Formoterol Extra-Fine Combination. Evidence and Future Perspectives. <i>Pneumologie</i> , 2009, 63, S102-S106.	0.1	4
229	Activation of NF- \hat{B} transcription factor in asthma death. <i>Histopathology</i> , 2009, 54, 507-509.	1.6	19
230	MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. <i>Histopathology</i> , 2009, 55, 321-331.	1.6	83
231	Inhibition of PI3K \hat{I} Restores Glucocorticoid Function in Smoking-induced Airway Inflammation in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 542-548.	2.5	222
232	Rescue Treatment in Asthma. <i>Chest</i> , 2009, 135, 1628-1633.	0.4	36
233	Clinical Definition of COPD Exacerbations and Classification of Their Severity. <i>Southern Medical Journal</i> , 2009, 102, 277-282.	0.3	21
234	Treatment strategies in mild asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 29-34.	1.2	3

#	ARTICLE	IF	CITATIONS
235	New drugs targeting Th2 lymphocytes in asthma. <i>Journal of Occupational Medicine and Toxicology</i> , 2008, 3, S6.	0.9	47
236	Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. <i>Nature Medicine</i> , 2008, 14, 199-204.	15.2	339
237	Inhaled beclomethasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 479-490.	0.9	48
238	Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma. <i>Expert Review of Respiratory Medicine</i> , 2008, 2, 161-166.	1.0	13
239	Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13562-13567.	3.3	447
240	Role of Xanthine Oxidase Activation and Reduced Glutathione Depletion in Rhinovirus Induction of Inflammation in Respiratory Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 28595-28606.	1.6	50
241	IL-32, a Novel Proinflammatory Cytokine in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 894-901.	2.5	146
242	Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 855-864.	0.9	28
243	Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. <i>New England Journal of Medicine</i> , 2007, 356, 2040-2052.	13.9	320
244	A Human Rhinovirus Model of Chronic Obstructive Pulmonary Disease Exacerbations. , 2007, 14, 101-112.		5
245	Matrix Metalloproteinase-2 Protein in Lung Periphery Is Related to COPD Progression. <i>Chest</i> , 2007, 132, 1733-1740.	0.4	65
246	Models of infection and exacerbations in COPD. <i>Current Opinion in Pharmacology</i> , 2007, 7, 259-265.	1.7	9
247	Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2007, 1, 171-175.	1.0	7
248	Pathophysiology of viral-induced exacerbations of COPD. <i>International Journal of COPD</i> , 2007, 2, 477-83.	0.9	13
249	Alteration of Adenosine Receptors in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 398-406.	2.5	101
250	Interactions between long-acting β_2 -agonists and glucocorticoids. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 261-268.	0.5	3
251	Up-Regulated Membrane and Nuclear Leukotriene B4 Receptors in COPD. <i>Chest</i> , 2006, 129, 1523-1530.	0.4	34
252	Role of deficient type III interferon- β production in asthma exacerbations. <i>Nature Medicine</i> , 2006, 12, 1023-1026.	15.2	955

#	ARTICLE	IF	CITATIONS
253	Pathophysiology of Exacerbations of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 245-251.	3.5	139
254	Smoking History Effect on Peripheral Lung Inflammation and Gene Transcription in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 2-3.	2.5	2
255	Telithromycin in Acute Exacerbations of Asthma. New England Journal of Medicine, 2006, 355, 96-98.	13.9	4
256	Molecular Mechanisms of Respiratory Virus-Induced Asthma and COPD Exacerbations and Pneumonia. Current Medicinal Chemistry, 2006, 13, 2267-2290.	1.2	25
257	Expression of Programmed Death-1 Ligand (PD-L1), PD-L2, B7-1, and Inducible Costimulator Ligand on Human Respiratory Tract Epithelial Cells and Regulation by Respiratory Syncytial Virus and Type 1 and 2 Cytokines. Journal of Infectious Diseases, 2006, 193, 404-412.	1.9	89
258	Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1114-1121.	2.5	901
259	Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease?. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 77-83.	1.1	40
260	Endothelial Cell Activity in Chronic Obstructive Pulmonary Disease Without Severe Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 435-440.	0.7	12
261	Sputum substance P and neurokinin A are reduced during exacerbations of chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2005, 18, 199-205.	1.1	11
262	Induction and regulation of matrix metalloproteinase-12 in human airway smooth muscle cells. Respiratory Research, 2005, 6, 148.	1.4	86
263	Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2005, 116, 1028-1035.	1.5	127
264	COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax, 2004, 59, 679-681.	2.7	184
265	Mechanisms of rhinovirus-induced asthma. Paediatric Respiratory Reviews, 2004, 5, 255-260.	1.2	76
266	Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 418-424.	2.5	445
267	Molecular Mechanisms of Respiratory Virus-Induced Inflammation. , 2003, , .		0
268	Airway Inflammation in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 105-110.	2.5	210
269	Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells. FASEB Journal, 2002, 16, 1934-1936.	0.2	52
270	Increased Expression of the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in Peripheral Airways of Smokers with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1404-1409.	2.5	321

#	ARTICLE	IF	CITATIONS
271	Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 221-228.	1.5	47
272	The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. <i>Journal of Clinical Investigation</i> , 2001, 107, 1357-1364.	3.9	388
273	Goblet Cell Hyperplasia and Epithelial Inflammation in Peripheral Airways of Smokers with Both Symptoms of Chronic Bronchitis and Chronic Airflow Limitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 1016-1021.	2.5	296
274	Partial Reversibility of Airflow Limitation and Increased Exhaled NO and Sputum Eosinophilia in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1773-1777.	2.5	243
275	Rhinovirus Infection Induces Major Histocompatibility Complex Class I and Costimulatory Molecule Upregulation on Respiratory Epithelial Cells. <i>Journal of Infectious Diseases</i> , 2000, 181, 1780-1784.	1.9	62
276	Rhinoviruses Infect the Lower Airways. <i>Journal of Infectious Diseases</i> , 2000, 181, 1875-1884.	1.9	503
277	Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-regulation and promoter activation on respiratory epithelial cells. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 318-326.	1.5	58
278	RANTES, Macrophage Inhibitory Protein 1?, and the Eosinophil Product Major Basic Protein Are Released into Upper Respiratory Secretions during Virus-Induced Asthma Exacerbations in Children. <i>Journal of Infectious Diseases</i> , 1999, 179, 677-681.	1.9	80
279	Rhinovirus Infection Induces Expression of Its Own Receptor Intercellular Adhesion Molecule 1 (ICAM-1) via Increased NF- κ B-mediated Transcription. <i>Journal of Biological Chemistry</i> , 1999, 274, 9707-9720.	1.6	322
280	Respiratory Epithelial Cell Expression of Vascular Cell Adhesion Molecule-1 and Its Up-regulation by Rhinovirus Infection via NF- κ B and GATA Transcription Factors. <i>Journal of Biological Chemistry</i> , 1999, 274, 30041-30051.	1.6	89
281	Bronchopulmonary inflammation and airway smooth muscle hyperresponsiveness induced by nitrogen dioxide in guinea pigs. <i>European Journal of Pharmacology</i> , 1999, 374, 241-247.	1.7	8
282	Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. <i>Thorax</i> , 1998, 53, 803-808.	2.7	40
283	Xanthine oxidase activity in bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary disease. <i>Free Radical Biology and Medicine</i> , 1996, 21, 147-155.	1.3	63
284	Oxygen radical scavengers inhibit clastogenic activity induced by sonication of human serum. <i>Free Radical Biology and Medicine</i> , 1994, 16, 363-371.	1.3	13
285	Toluene diisocyanate-stimulated release of arachidonic acid metabolites in the organ bath from guinea-pig airways. <i>European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section</i> , 1993, 248, 277-280.	0.8	3
286	The effect of compound on contractions induced by toluene diisocyanate in isolated guinea-pig bronchus. <i>European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section</i> , 1993, 248, 67-73.	0.8	8
287	The products of the reaction between toluene diisocyanate and water contract isolated guinea pig bronchi. <i>European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section</i> , 1992, 228, 103-106.	0.8	3
288	Asthma: definition, severity and impact of pulmonary exacerbations. , 0, , 1-12.		2

#	ARTICLE	IF	CITATIONS
289	Steroid-Sparing Strategies: Other Combinations. , 0, , 187-206.		0